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The genetic liver disease, acute intermittent porphyria (AIP),' is character-
ized biochemically by the excessive production and excretion into urine of the
tetrapyrrole precursors, 6-aminolevulinic acid (ALA) and porphobilinogen
(PBG). This unique excretion pattern of intermediates of the porphyrin-heme
pathway distinguishes AIP from the two other hereditary forms of hepatic
porphyria, variegate porphyria and hereditary coproporphyria. Increased activ-
ity of the porphyrin-heme synthetic pathway in all three genetic disorders
results from increased hepatic levels of ALA-synthetase, the mitochondrial
enzyme which is rate-limiting for the pathway Z1).
It is only in AIP, however, that excessive amounts of porphyrin precursors
rather than of porphyrins themselves are produced, suggesting that there is in
this disease a biochemical defect of the pathway localized at a step after the
formation of PBG. Indeed, the activity of the hepatic enzyme which catalyzes
the formation ofuroporphyrinogen I from PBG-uroporphyrinogen I synthetase
(URO-S)-has been shown to be considerably decreased from normal levels in
AIPbut not inother forms ofhereditary hepaticporphyrias (2, 3). More recently,
Meyer et al. (4, 5) and our own group (6, 7) have shown that URO-S activity is
also markedly deficient in the erythrocytes of AIP patients. The decreased
activity of URO-S in AIP subjects readily accounts for the impaired conversion
of PBG to porphyrins and thus the excessive excretion of both ALA and PBG
into urine.
One parent of each set and certain siblings and offspring of AIP patients
display low levels of erythrocyte URO-S activity; pedigree studies clearly show
thatthis enzymedeficiency is inherited in an autosomal dominant pattern (4-7).
AIP patients, as well as their relatives with low URO-S activities, thus repre-
sent the heterozygous state for the gene defect ofthis enzyme, and such individ-
* These studies were supported by U.S. Public Health Service General Clinical Research
Center grant RR-102, National Foundation grant I-350,and National Foundation Birth Defect
contract no. 74140.
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ria; PBG, porphobilinogen; URO-S, uroporphyrinogen I synthetase .
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uals may be considered to be carriers of the AIP trait. However, it is clear (7)
that a deficiency of URO-S activity does not, in itself, account for the clinical
syndrome characterizing AIP, and that endocrine (8-10) as well as other meta-
bolic factors must be involved in determining the clinical expression of the
disorder.
In this report we show that the URO-S defect found in the liver and erythro-
cytes ofAIP subjects can readily be identified in cultured skin fibroblasts from
such patients, utilizing a newly developed, simple, and sensitive assay for
detection of this enzymatic abnormality. In addition, in studies of cultured
human amniotic cells, evidence has been obtained which has permitted us to
make the first prenatal diagnosis ofthe gene carrier state for AIR
Materials and Methods
Study Subjects.
￿
Atotal of eight AIPpatients were studied with skin fibroblast cultures. They
were femaleswith the age rangeof31-60. Thediagnosis of AIP was established by characteristic
clinical features together with an excessive urinary ALA and PBG excretion, in addition to the
decreasederythrocyte URO-S activity typical forAIP patients (4-7). Amatched groupof12 normal
subjects was studied as controls.
Human amniotic cells were obtained by amniocentesis from a total of 25 pregnant females
during induced abortion requested by the mothers and performed with written consent at the
SUNY Downstate Medical Center. Theageoftheabortedfetuses ranged from 13 to 22 wk andthat
of the mothers was 14-33 years. Amniotic cells were also obtained from apregnant AIP female at
herrequestduring the17th wk ofgestation. Ultimately the mother decidedto allowthe pregnancy
to go on to completion.
Cell Cultures.
￿
An approximately0.5 x 1 x 3 mm piece of skin specimen was biopsied from the
upper forearm and cut into 7-10 pieces in 1 ml of growth medium in a 60-mm dish. The growth
medium was Ham F12-20% heat-inactivated fetal bovine serum containing penicillin (100 U/ml)
and streptomycin (100 Wg/ml) (F12-20% FBS). Mycostatin was not included since it was found
slightly inhibitory forcell growth at a concentration of 25 U/ml. Phenol redwasalso avoidedsince
it interferes with the porphyrinfluorescence assay. The fetal bovine serum(Grand Island Biologi-
cal Co., Grand Island, N.Y.) used was abatch previously selected for optimumability to support
cell growth. Two-three pieces of skin specimens were then transferred into each of three 25-cm'
plastic culture flasks (Falcon no. 3013, Falcon Plastics, Div. of BioQuest, Oxnard, Calif.) with a
minimumamount of F12-20%FBS.They were incubatedat 37°C for1-2 h to allow adhesion to the
flask. Then 5 ml of F12-20% FBS wasgently introduced into theflask andthecells were incubated
at 37°C in 5% C02-95% air. Thegrowth medium wasreplenished approximatelyevery2wk atthe
beginning of culture, then subsequently everyweek.
When the fibroblasts reached local confluency, approximately 3-6 wk after the initiation of
culture, thecells were rinsed with 5 ml Earle's buffer salt solution devoid ofCa"andMg", then
incubated with 1.0 ml 0.25% trypsin-0.02% EDTA (GIBCO) at 37°C for 5-10 min. After the cells
were detached from theflask as a suspension of single cells, 10 ml of F12-20%FBS was added and
two 5-ml aliquots were transferred to 25-cm2flasks.In this way, cells were subcultured three-four
timesforapproximately 3 mo to obtain sufficient quantities of cells.
Cells obtained from 20-50 ml of human amniotic fluid were grown in 75-cm2 culture flasks
(Falcon, no. 3024) in McCoy's 5A medium supplemented with 20% heat-inactivated fetal bovine
serum or F12-20% FBS. In some instances cell suspensions in amniotic fluid were incubated
without supplementation of growth medium. After the cells were attached to the flask, growth
medium was provided. Amniotic cells were subcultured as described for skin fibroblasts. After
approximately 2-10 wk of growth in F12-20% FBS, sufficient numbers of cells were obtained to
perform enzyme assays.
URO-S Assay in Cultured Amniotic Cells .
￿
Thefluorometric microassay forURO-S activity in
erythrocytes described by Sassa et al. (7) was applicable to these cells with minor modification
(60°C incubation rather than 37°C). 1 day before the experiment, the medium of early confluent
cultures was changed to a freshmedium (F12-20% FBS) andthe cellswere incubatedfor afurther724 STUDIES IN PORPHYRIA. IV
24 h before harvesting before the assay. The cells were harvested from a 75-cm' flask by 0.25%
trypsin-0.02% EDTA (pH 7) andwashed once in 10 ml of F12-10% FBS andsuccessively twice in 5
ml of Earle's buffer salt solution. The final cell pellet was suspended in 200 jul of 0.1 Mphosphate
buffer (pH 7.4) andhomogenized in a microhomogenizer equipped with ateflon pestle. 20 p.l of the
homogenate was mixed with 5 Al of 500 WM porphobilinogen (PBG) in 0.1 Mphophate buffer (pH
7 .4) in a6 x50 mm disposable glass tube andsealed with a piece of parafilm. Themixturewasthen
incubated in duplicate at 60°C for 1 h in the dark. Incubation wasterminated by coolingthetube in
ice and the product, URO, was extracted as described previously (7). Porphyrin fluorescence was
determined in thesame incubation tube without transfer ofthematerial by inserting thetube into
the specially constructed microcell holder shown in Fig. 1. This cell holder wasdesigned to fit the
FIG. 1.
￿
A microcell holder (6-mm diameter tubes) for the Hitachi-Perkin Elmer fluores-
cence spectrophotometer. The holder was modified after a Perkin-Elmer microcell holder
(cat. no. 010-0501).
cell component oftheHitachi-Perkin ElmerMPFseries spectrofluorometer (Hitachi-Perkin Elmer
Instruments, Norwalk, Conn.) andgreatly facilitates themicroassay which wasdeveloped for this
enzyme activity (7). Two control tubes were run: one tube was without cell material for a control
on the nonenzymatic conversion of PBG to porphyrin, the other control was run without PBG in
order to determine endogenous levels of porphyrin. These controls were incubated and treated as
described above and the sumofthetwo sets of control values was subtracted from the experimen-
tal value. The range of the sum control values was 33-74% those of the complete mixture.
ALA-Conversion to Porphyrin by Cultured Skin Fibroblasts.
￿
The ability of skin fibroblasts in
culture to convert ALA or PBG to porphyrins was studied with the intent to develop a precise
assay for detecting the presence of URO-S deficiency in such cells, since as noted above with
amniotic cells the considerable extent of nonenzymatic conversion of PBG to porphyrin in the
direct URO-S assay on homogenized cells mayintroduce potential errors in the assay. Fibroblasts
grown in 25-cm' flasks were subcultured as described above andapproximately 6-9x 105 cells were
placed into each 1.8-cm' well of a FB16-24TC plate (Linbro Chemical Co., Inc.) with 0.5 ml of F12-
20% FBS. A total of 24 wells was prepared for each study subject. After 6 days ofgrowth, medium
was removed and 1 ml of Ham F12 supplemented with insulin (1 Fig/ml) (F12-Insulin) was added.
10 Al of ALA(10 mg/ml) wasadded to the growth medium andincubation wascontinued for 24 h, at
37°C in 5% C02-95% air. After theincubation, themedium wasremovedandthe cells were washed
once with 1 ml Earle's buffer salt solution. In order to extract porphyrins 500 Al of 1N perchloric
acid-methanol (1 :1 vo]Jvol) mixture was then added to the cells with gentle rotation. After 5 min
the perchloric-methanol solution was removedinto a 6 x 50 mm glass tube andthefluorescence of
the extract wasdetermined in the micro-cell holder shown in Fig. 1. In order to determine protein
concentration, 200 1.41 of 0.5 N NaOH was added to the cells and they were heated at 60°C for 1 h,
then diluted up to 1 ml with water. Protein concentration was determined on the cellular digests
by the method of Lowry et al., using bovine serum albumin as standard (11).S. SASSA, G. SOLISH, R. D. LEVERE, AND A. KAPPAS
￿
725
Results
URO-S Activity in Cultured Amniotic Cells.
￿
The activity of URO-S was
demonstrable directly in cells centrifuged from fluid derived from the amniocen-
tesis procedure . However, meaningful results could not be obtained by utilizing
such cells because of the presence of contaminating erythrocytes and numerous
dead amniotic cells. By growing amniotic cells in tissue culture, however, it was
possible to cultivate sufficient quantities of viable cells for the enzyme assay.
The use of elevated temperature to increase the sensitivity of the URO-S
assay was proposed by Meyer (12). This procedure takes advantage of the
unusual heat stability of URO-S, e .g., the T/2 of this enzyme activity at 70°C is
45 min (7). Although the other enzyme involved in formation of the type III
uroporphyrinogen isomer, URO-cosynthetase, is destroyed at this temperature
(13, 14), the rate of formation of total uroporphyrinogen is not affected, since
URO-S which is highly heat-stable is rate-limiting for tetrapyrrole formation
from PBG (5, 7, 13, 14) .
The rate of the URO-S reaction is increased approximately fourfold at 60°C as
compared to 37°C. The course of the reaction is linear with time for 60 min, and
the complete mixture, i.e . enzyme plus substrate, is required for maximal
porphyrinogenesis (15). The rate of enzyme activity is also directly proportional
to the amount of enzyme protein added to the mixture (15) .
The results of a number of experiments utilizing cultured amniotic cells are
summarized in Table I. The mean value of URO-S activity in amniotic cell
cultures from 25 pregnant females was 57 .4 ± SE of 5.2 pmol URO/mg pro-
tein, h, 60°C. These data demonstrate that cultured amniotic cells are able to
condense 4 mol of the monopyrrole PBG to the tetrapyrrole uroporphyrinogen.
Other evidence obtained in our laboratory indicates that the entire biosynthetic
sequence for heme exists in cultured amniotic cells. However, the potent inducer
of ALA-synthetase in liver cells, allylisopropylacetamide, does not stimulate
porphyrinogenesis in amniotic cells, suggesting that the response of amniotic
cells to exogenous chemicals may be quite different from that of liver cells (16) .
ALA Conversion to Porphyrin by Cultured Skin Fibroblasts.
￿
When cultured
fibroblasts were incubated in the presence of PBG, the immediate substrate for
URO-S, the monopyrrole proved to be extremely cytotoxic even when added in
very low concentrations to the cultures. However, it proved possible to circum-
vent this problem by adding ALA (100 wg/ml), the precursor of PBG, to the
cultures rather than the monopyrrole itself. Viability of cells was more than 95%
for both untreated and ALA-treated cells as judged from trypan blue exclusion.
When the cells were incubated with ALA in F12-Insulin for 24 h, the porphyrin
accumulation was linearly increased as a function ofALA concentration up to 50
Wg/ml (Fig. 2). When the cells were incubated in F12-Insulin with ALA 100
jig/ml, porphyrin in the cells increased essentially linearly until 24 h (Fig. 3).
However, when the medium contained 10-20% FBS, porphyrin accumulation in
the cells was less than 1/lo that obtained when the cells were incubated with F12-
Insulin (Figs. 2, 3), in keeping with the comparable findings of Granick et al .
(17), who used cultured avian hepatic cells. The decreased porphyrin accumula-
tion in the cells in the serum-containing medium was due both to inhibition of726
TABLE I
URO-S Activity in Erythrocytes and Cultured Amniotic Cells from a Child Carrying the
AIP Gene Defect Born to a Woman with Clinically Manifest AIP
Cells
Mother (active AIP), 32 yr
Father (normal), 32 yr
Baby (AIP carrier), 15 mo
Son 1 (normal), 11 yr
Son 2 (AIP carrier), 4 yr
Mother's sister (normal), 30 yr
Normal subjects
AIP patients
* Assays were performed as described in ref. 7 with 100 AM PBG.
$ A range of three determinations.
§ Mean ± SE (number ofcases) .
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URO-S activity
Erythrocytes*
￿
Amniotic cells
nmol URO/ml RBC,
￿
pmol UROlmg protein,
h, 37°C
￿
h, 60°C
14 .5
26.1
11 .2
￿
0-12$
32 .0
13 .4
32.4
28.7 ± 6.8 (64)§
￿
57.4 ~ 5.2 (25)§
15.3±4.5(10)§
O 10 20
￿
50
￿
100
ALA (Ng/ml )
F12-FBS
FIG. 2.
￿
Porphyrin accumulation in cultured human skin fibroblasts as a function of ALA
concentration. Cells were incubated at 37°C for 24 h in the presence of either F12-Insulin
(0-") or F12-10% FBS (0-0) together with ALA. Essentially all the porphyrin formed
was identified as protoporphyrin IX from its characteristic fluorescence emission spectrum.
Extraction and quantitation of porphyrin are described in the Materials and Methods
section.
porphyrin formation from ALA and to its loss from the cells into the growth
medium.
The porphyrin which accumulated in the cells and in the medium was
identified by its characteristic fluorescence spectrum (19) and proved to beS . SASSA, G . SOLISH, R . D . LEVERE, AND A . KAPPAS
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FIG . 3 .
￿
Porphyrin formation from ALA in culturedhuman skin fibroblasts as a function of
time . Cells were incubated at 37°C with ALA (100 Wg/ml) in the presence of either F12-
Insulin ("-") of F12-10% FBS (O-O) . Extraction and quantitation of porphyrin are
described in the Materials and Methods section .
almost entirely protoporphyrin IX . Since protoporphyrin was formed in large
amounts from ALA, it is clear that cultured human skin fibroblasts contain all
enzymes of the heme pathway from ALA-dehydratase to coproporphyrinogen
decarboxylase in nonlimiting amounts. Other evidence from our laboratory
(unpublished data) indicates that the terminal enzyme activity of the heme
biosynthetic pathway, i.e ., ferrochelatase, is also present in these fibroblasts in
culture but becomes limiting under the conditions of these studies . Although
ALA-dehydratase activity in fibroblasts is too low to measure using the pres-
ently available colorimetric assay techniques, it can be reasonably supposed
that this enzyme activity in AIP fibroblasts is not different from those of
normals, since ALA-dehydratase activity in erythrocytes of AIP patients is
normal (6) . Moreover, ,there is no indication in this disorder for a decrease in
ALA-dehydratase activity as judged from the excretion pattern of porphyrin
precursors ; and specific data showing normal levels of the enzyme activity in
AIP liver have been provided by Nakao et al . (20) .
The results of the experiments with ALA additions to the fibroblast cultures
are summarized in Fig. 4 . The mean protoporphyrin formation from ALA by
skin fibroblastsfrom 12 normal individuals was 547 with SE ± 18 pmol protopor-
phyrin/mg protein, 24 h. In contrast, the mean value for cells from eight AIP
patients was 192 with SE ± 14 pmol protoporphyrin/mg protein, 24 h-approxi-
mately 40% of the value found in normals (P < 0.001) . It can thus be concluded
that the rate-limiting step of protoporphyrin formation from ALA in these
cultured cells is at the level ofURO-S and that the markedly decreased URO-S
activity in cells from AIP patients may be readily detected by determining the
porphyrin concentration in the cells after incubation with ALA.
URO-S activity directly assayed in these cells was 40.9 ± 11 .8 (mean -L SE)728
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Ftc . 4 .
￿
Porphyrin formation from ALA in cultured skin fibroblasts from 12 normal sub-
jects and 8 AIP patients . The height of the columns represents a mean value with the SE
indicated for each group .
pmol URO/mg protein, h, 60°C, for six normal individuals and 12 .4 ± 2.7 pmol
URO/mg protein, h, 60°C, for five All? patients . Thus, it was also possible to
show the gene defect of the All? disorder by the direct enzyme assay, confirming
the findings of Meyer (12), and Bonkowsky et al . (18) . However, the levels of the
enzyme activity in AIP fibroblasts were at the lowest limit of detection of the
assay, thus introducing potential inaccuracy in the determination . On the other
hand, our new technique of quantitation of porphyrin formation from ALA by
fibroblasts in culture yields far better reproducibility plus greater sensitivity
and ease of application while reflecting the genetically determined decrease in
level ofURO-S in the cells from AIP patients .
Prenatal Diagnosis of a Gene Carrier ofAIP .
￿
Amniotic cells derived from a
pregnant patient with clinically manifest All? who had low URO-S activity in
both her skin fibroblasts and erythrocytes, exhibited a markedly lower level of
URO-S activity compared to normals (Table 1) . Other enzymes used as markers,
e.g ., glucose-6-phosphate dehydrogenase, were normal (data not shown) in the
amniotic cells of this fetus ; therefore the deficiency of URO-S activity found in
the amniotic cells was a specific defect of this fetus .
This pregnancy went on to completion and 15 mo after birth, the child, a girl,
exhibited a deficient level of erythrocyte URO-S activity typical of that which
characterizes AIP patients-including the mother, and which was one-half the
level of the enzyme activity found in the erythrocytes of her normal father,
normal aunt, and normal sibling (Table I).The diagnosis was further confirmed
by a decreased porphyrin formation from ALA in the child's skin fibroblasts in
culture .
Discussion
The results of the present study indicate that in All? patients a marked
deficiency of URO-S activity can be easily detected in cultured skin fibroblastsS. SASSA, G. SOLISH, R. D. LEVERE, AND A . KAPPAS
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by quantitating the ability of such cells to synthesize protoporphyrin from the
porphyrin precursor, ALA. The extent ofthe URO-S deficiency found in fibro-
blasts by this technique is comparable to that found earlier in the liver and
erythrocytes of AIP patients, i.e. approximately 50% less than normal (4-7).
Though the enzyme deficiency in AIP could be demonstrated directly (Results
section) using homogenizedfibroblasts withthe substrate PBG as also indicated
by Meyer (12) and Bonkowsky et al. (18), the quantitative assay of URO-S
activity in fibroblast homogenates in our studies presented several major draw-
backs, viz there was a wide variation (fivefold) of the enzyme activity, a large
amount oftissue was required for the assay (1-2 mg protein), and the levels of
the enzyme activityfoundin AIP cells were at the lowest limit ofdetection ofthe
method, thus increasing the potential error of the determination. For these
reasons, the technique described here for the indirect assay ofURO-S activity
was developed.
The principle of the assay depends on the fact that ALA enters the cultured
fibroblasts, that the cells readily convert the exogenous ALA to protoporphyrin,
and that the rate of this conversion is limited solely by the level of URO-S
activity in the cells. This assay was made possible by the finding that PBG
generated intracellularly from added ALA is not toxic, in contrast to exoge-
nously added PBG which is extremely toxic to the cells. The assay technique is
simple and has distinct advantages compared to the direct measurement of
URO-S activity. For example, the extraction of porphyrin and its quantitation
are easily accomplished and the assay can be performed with the small amount
ofcells grown in a 1.8 cm' well. The cultured cells accumulate protoporphyrin
without significant lossofitinto the medium or itsfurther metabolic conversion
in the cultures. Thus, the amounts of porphyrin formed exceed by almost five-
fold the amounts formed by previously describedtechniques (18). Moreover, the
assay reflects the enzyme activity found in living cells, rather than that ex-
pressed in a fraction of a cell homogenate resulting in a great increase in the
sensitivity of the assay. Finally, the variability of the assay described is ex-
tremely small, replicate determinations from specific cultures having anSE less
than ± 3%.
It should be also notedthatthevariationfoundbetweenindividuals in normal
and in AIP groups by this technique is much smaller than that found in
erythrocytes (7) from the same population groups. The reason for the greater
variation of erythrocyte enzyme activities is not understood, although it is
possible that the specialized turnover and life cycle of red cells complicate the
expression ofgenetically determined levels of enzyme activities in such cells. In
keeping with this idea, we have recently demonstrated that URO-S activity is
significantly higher in reticulocytes than in mature erythrocytes (unpublished
observations).
It was possible, in the course of this study, to demonstrate that cultured
amniotic cells derived from a pregnant woman with clinically manifest AIPhad
a markedly decreased level of URO-S activity as compared with normal cells
(Table I). Subsequently, a deficiency of URO-S activity was confirmed in the
erythrocytes ofthe child in question, 15 mo after herbirth. This case study thus
represents the first demonstration of the diagnosis of an AIP gene carrier in730
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utero and indicates the potential usefulness of the URO-S assay in amniotic cells
for prenatal detection of the AIP gene defect.
Summary
The gene lesion of the porphyrin-heme synthetic pathway in acute intermit-
tent porphyria (AIP) is reflected in a deficient level of activity of the cytosol
enzyme uroporphyrinogen I synthetase (URO-S) . A marked URO-S deficiency
has been demonstrated in the liver and in circulating erythrocytes ofindividuals
with both active and latent AIP. This enzymic abnormality accounts for the
excessive production and excretion into urine of the porphyrin precursors, S-
aminolevulinic acid (ALA) and porphobilinogen (PBG) in AIP subjects . In this
study, utilizing cell culture techniques, a marked URO-S deficiency has also
been demonstrated in skin fibroblasts from AIP patients and in cells derived
through amniocentesis from an approximately 17-wk old fetus. The prenatal
diagnosis of the AIP trait in this fetus was confirmed postnatally by the
demonstration in the child of a deficient level of erythrocyte URO-S activity
which was comparable to those found in her AIP mother and an affected sibling
and which was approximately one-half the levels characterizing her normal
father and aunt and a second unaffected sibling.
The identification ofthe URO-S deficiency in cultured human fibroblasts from
AIP patients was facilitated by a newly developed, sensitive assay for the
enzyme activity. In this assay, the ability of such cells to convert ALA to
protoporphyrin was quantitated ; in the sequence of reactions involved in this
transformation, URO-S is limiting so that the gene defect ofAIP could be simply
and precisely determined by appropriate spectrofluorometry ofcell extracts. The
technique described has distinct advantages over the direct enzymatic assay for
URO-S activity in cultured human skin fibroblasts and permits clear differentia-
tion of AIP carriers from normal individuals.
The authors are indebted to Doctors Karl Anderson and Peter N . Gillette for their clinical
assistance, to Mrs. Chin Chang and B. Weiss for excellent technical assistance, and to Miss Ann
Marie Quatela for the preparation of this manuscript.
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